Skip to content

WHO-Aligned Changes Proposed for Indian Sterile Drug Manufacturing

By News Analysis India · · 1 min read

India’s pharmaceutical regulatory landscape is set to undergo a significant update following a proposal from the Central Health Ministry. On October 28, the ministry released GSR Number 953(E), outlining necessary revisions to Schedule M of the Drugs Rules, 1945. The primary objective is to recalibrate microbial contamination limits for Grade A sterile manufacturing areas.

This regulatory shift is designed to bring national standards in line with the World Health Organization’s TRS No. 1044, Annex 2. By addressing existing variations between Indian limits and global benchmarks, the amendment seeks to fortify India’s pharmaceutical quality control mechanisms.

Grade A environments are indispensable in sterile pharmaceutical production, serving as the controlled spaces for handling sensitive products and sterile packaging. The updated guidelines will mandate stricter microbial monitoring, ensuring that manufacturing facilities maintain the highest levels of cleanliness and safety.

Notably, the draft introduces a strict compliance trigger: any trace of microbial contamination in Grade A zones will require immediate regulatory action and investigative protocols. This provision reinforces the ministry’s dedication to enhancing domestic regulatory frameworks and guaranteeing patient safety.

The proposed adjustments reflect a broader governmental strategy to synchronize local pharmaceutical requirements with globally recognized quality metrics. To ensure broad stakeholder input, the ministry has opened a consultation window. Industry experts, manufacturers, and citizens may email their suggestions or formal objections to the Additional Secretary (Drugs Regulation).